MAP Publication

Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

2017 |

Conducting an adequately powered survival study in idiopathic pulmonary fibrosis (IPF) is challenging due to the rare nature of the disease and the need for extended follow-up.

This aim of this analysis was to predict life expectancy for patients with IPF receiving pirfenidone versus best supportive care (BSC) in a population that met the inclusion criteria of patients enrolled in the ASCEND and CAPACITY trials.

The article is available here.


All Publications